Myriad Announces Favorable Medicare Final Coverage Decision for the ProlarisR) Test

Myriad Genetics, Inc.

today announced that Noridian, the Medicare Administrative Contractor (MAC) for Myriad, has issued a final local coverage determination (LCD) for Prolaris®, Myriad's pioneering prognostic test for assessing the aggressiveness of prostate cancer. This decision follows a final LCD decision from Palmetto GBA on January 15, 2015. The final LCD is posted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Services website with an effective date of October 15, 2015 and provides Medicare coverage for prostate cancer patients defined as low and very low risk by the National Comprehensive Cancer Network (NCCN). The Medicare coverage decision extends reimbursement for testing to the approximately 60,000 patients diagnosed each year with localized prostate cancer in the United States who meet the criteria of a Gleason score ≤6 and serum prostate specific antigen (PSA) level <10 ng/ml.  "We are excited that Noridian has issued a final LCD for Prolaris, providing coverage for Medicare beneficiaries with localized prostate cancer," said Mark Capone, president and CEO, Myriad Genetics, Inc. "The decision is an important step in providing Medicare reimbursement for this life-saving test and will significantly increase patient access to Prolaris testing in the United States." More